These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38269536)

  • 1. Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by
    Vadagam P; Waters D; Lee I; Chen J; Tian D; Near AM; Lyle D; Vanderpoel J
    J Med Econ; 2024; 27(1):219-229. PubMed ID: 38269536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India.
    Singh V; Nambirajan A; Malik PS; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Mohan A; Jain D
    Lung Cancer; 2020 Nov; 149():53-60. PubMed ID: 32971387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, Treatment Patterns, and Outcomes of Individuals with
    O'Sullivan DE; Jarada TN; Yusuf A; Hu LXY; Gogna P; Brenner DR; Abbie E; Rose JB; Eaton K; Elia-Pacitti J; Ewara EM; Pabani A; Cheung WY; Boyne DJ
    Curr Oncol; 2022 Sep; 29(10):7198-7208. PubMed ID: 36290844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.
    Shenolikar R; Liu S; Shah A; Tse J; Cao Y; Near A
    Cancer Med; 2023 Jan; 12(1):159-169. PubMed ID: 35702932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India.
    Garg A; Batra U; Choudhary P; Jain D; Khurana S; Malik PS; Muthu V; Prasad KT; Singh N; Suri T; Mohan A
    Curr Probl Cancer; 2020 Jun; 44(3):100570. PubMed ID: 32498966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].
    Liu JJ; Zhang S; Wu CJ; Ma LX; Liu Y; Li H; Cui HX; Cheng Y
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):211-7. PubMed ID: 26988828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
    Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L
    Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Subramanian J; Fernandes AW; Laliberté F; Pavilack M; DerSarkissian M; Duh MS
    Lung Cancer; 2019 Dec; 138():131-138. PubMed ID: 31733614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
    Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
    Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
    Leduc C; Merlio JP; Besse B; Blons H; Debieuvre D; Bringuier PP; Monnet I; Rouquette I; Fraboulet-Moreau S; Lemoine A; Pouessel D; Mosser J; Vaylet F; Langlais A; Missy P; Morin F; Moro-Sibilot D; Cadranel J; Barlesi F; Beau-Faller M;
    Ann Oncol; 2017 Nov; 28(11):2715-2724. PubMed ID: 28945865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
    Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
    Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
    Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K
    Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer.
    Batra U; Biswas B; Prabhash K; Krishna MV
    BMJ Open Respir Res; 2023 Jun; 10(1):. PubMed ID: 37321664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
    Hellyer JA; White MN; Gardner RM; Cunanan K; Padda SK; Das M; Ramchandran K; Neal JW; Wakelee HA
    Clin Lung Cancer; 2022 May; 23(3):264-272. PubMed ID: 34838441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
    Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
    Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
    Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.